Upload
anca-iulia-neagu
View
241
Download
0
Embed Size (px)
Citation preview
7/22/2019 IHC- interpretare.ppt
1/185
Markeri IHC in diagnosticul
tumorilor epiteliale si
conjunctive
7/22/2019 IHC- interpretare.ppt
2/185
BCL-2
Reacts with the BCL2 oncoprotein encoded by a gene involved in the t(14;18) chromosomal
translocation;
Bcl-2 ("B-cell lymphoma/leukaemia-2"), which acts as an inhibitor of apoptosis, was originally
discovered as a proto-oncogene in low-grade B-cell lymphomas.
In the adult organism Bcl-2 expression is generally confined to cells that are rapidly dividing and
differentiating. In lymphocytes, Bcl-2 is highly expressed in T-cells, pro-B cells and mature B-cells (wherelifespan is extended) while downregulated in germinal center B-cells (where apoptosis forms part of the
developmental pathway in order to select only cells producing antibodies with high avidity)
Overexpression of Bcl-2 is common in many types of cancer, including non-Hodgkin's lymphoma
and leukaemias, adenocarcinomas (e.g., prostate, colorectum, stomach, and lung), squamous cell
carcinoma, small cell carcinoma, neuroblastoma and various sarcomas. Among the latter, strong Bcl-2
positivity has particularly been demonstrated in gastrointestinal stromal tumor, solitary fibrous tumor, and
synovial sarcoma, while fibromatosis and "malignant fibrous histiocytoma" are usually negative.
Among malignant lymphomas, Bcl-2 protein overexpression is often caused by chromosomal translocation
(14;18) with Bcl-2 gene rearrangement. This is especially seen in follicular lymphoma. bcl-2 is expressed in
almost 100% of the grade I lymphomas, in >80% of the grade II and in 75% of the grade III lymphomas.
Follicular lymphoma of the skin is often bcl-2 negative
7/22/2019 IHC- interpretare.ppt
3/185
Bcl-2 in ggl limfaticBcl-2 in SLL
Bcl-2 in GIST
7/22/2019 IHC- interpretare.ppt
4/185
BCL-6:
encodes a 706 amino acid nuclear protein (repressor
of p53), is rearranged in about 30% of diffuse large B-
cell lymphomas, and is expressed predominantly innormal germinal center B cells and related
lymphomas;
The antibody gives a strong nuclear labeling of BCL6
protein in follicular lymphomas, diffuse large B-celllymphomas, Burkitt's lymphomas, and nodular,
lymphocyte-predominance Hodgkin's disease.
7/22/2019 IHC- interpretare.ppt
5/185
Bcl-6 in ggl limf Bcl-6 in limfom folicular
7/22/2019 IHC- interpretare.ppt
6/185
7/22/2019 IHC- interpretare.ppt
7/185
ALCLALK in ALCL
7/22/2019 IHC- interpretare.ppt
8/185
CD5-
The CD5 antigen is a 67 kDa transmembrane glycoprotein expressed on the surface of practically allmature human T-cells (about 10% of CD4+ T-cells being CD5 negative). In immature (CD34+) T-cells, CD5 is weakly expressed, the intensity of expression increasing with maturation.
CD5 is also expressed in a small subset of normal human B-cells (20% of B-cells in the peripheralblood, scattered cells in the lymph node mantle zone). The CD5+ cells are probably involved in B-Tinteraction and their ligand is CD72 which is expressed on all B cells.
It appears that CD5+ B-cells on activation primarily produce IgM. They also produce moreautoantibodies than normal CD5 negative B-cells. Thus, the CD5+ B-cell population is expanded inrheumatoid arthritis and systemic lupus erythematosus.
Neoplasms
CD5 is detected in most T-cell lymphomas and leukaemias, including 75% of peripheral T-celllymphomas and 85% of T-ALL cases. Lack of CD5 in the latter signifies a worse prognosis.
Among B-cell lymphomas, more explicit CD20+ small-cell lymphomas, small lymphocytic lymphoma
and mantle cell lymphoma are CD5+, whereas follicular lymphoma, marginal zone lymphoma andlymphoplasmacytoid lymphoma are CD5 negative. CD5 is detected in 5% of acute myeloidleukaemias.
CD5 has been detected in some cases of thymic carcinoma and atypical thymoma. Othercarcinomas are CD5 negative.
7/22/2019 IHC- interpretare.ppt
9/185
7/22/2019 IHC- interpretare.ppt
10/185
CD10 CD10 is a single-chain cell surface glycoprotein, 90-110 kDa, also designated
common acute lymhoblastic leukaemia antigen (CALLA)
CD10 is present on the cell surface of bone marrow stem cells andmyelopoietic cells (including neutrophils), follicular centre cells, few mature B-lymphocytes;
CD10 is also found in enterocytes in the upper part of the intestinal tract(brush border,in liver (bile canaliculi), kidney (glomerular and proximal tubularcells), pulmonary alveolar cells, myoepithelial cells of breast.
CD10 is expressed in most cases of precursor B lymphoblasticleukaemia/lymphoma, follicular lymphoma, and Burkitt lymphoma. CD10 isfound in some cases of diffuse large B-cell lymphoma, and mantle celllymphoma;
small lymphocytic lymphoma, marginal zone lymphoma, andlymphoplasmacytoid lymphomaare negative.
CD10 is found in almost all cases of endometrial stromal sarcoma, in mostcases of hepatocellular carcinoma (distinct canalicular pattern), renal cellcarcinoma (clear cell and papillary types, but not chromophobic type)
7/22/2019 IHC- interpretare.ppt
11/185
7/22/2019 IHC- interpretare.ppt
12/185
Limfom folicular Carcinom renal
7/22/2019 IHC- interpretare.ppt
13/185
CD15 a haematopoietic differentiation antigen expressed on
most terminally differentiated myeloid cells includinggranulocytes, eosinophils, mast cells,
monocytes/macrophages, and Langerhans' cells. The positivity for CD15 is characteristic of Hodgkins
cells in classical Hodgkins disease (HD);
It is expressed in great majority of nodular sclerosis(NS), mixed cellularity (MC), lymphocyte depletion(LD) and lymphocyte rich-classical HD cases, but not inmalignant cells of lymphocyte predominance (LP) HD(L&H cells, popcorn cells)
7/22/2019 IHC- interpretare.ppt
14/185
7/22/2019 IHC- interpretare.ppt
15/185
7/22/2019 IHC- interpretare.ppt
16/185
CD20 normal CD20 in CLL
7/22/2019 IHC- interpretare.ppt
17/185
CD23- low affinity IgE receptor, Leu-20, FceRII;
- In humans, main cellular expression of CD23 is found in B-lymphocytes(strong expression in activated germinal center B-cells, weaker stainingof resting mantle zone B-cells), monocytes, follicular dendritic cells(FDCs) predominately in the apical light zone of the germinal center;
- CD23 is typically expressed in chronic lymphocytic leukemia (CLL) - thestrongest expression is characteristically present in proliferationcenters.
- sometimes in follicular lymphoma,
- rarely in marginal zone and lymphoplasmacytic lymphoma,
- not in mantle cell lymphoma.- !! CD23 is also frequently used to demonstrate benign follicular
dendritic cells in the background of follicular lymphoma
7/22/2019 IHC- interpretare.ppt
18/185
7/22/2019 IHC- interpretare.ppt
19/185
CD30 CD30 is a member of the tumor necrosis factor receptor (TNF-R)
superfamily;
CD30 is found in activated B lymphocytes, plasma cells, Tlymphocytes, NK cells, monocytes;
CD30 is expressed in classical Hodgkins disease (cHD),anaplastic large cell lymphoma (ALCL), anaplastic variant ofdiffuse large B-cell lymphoma (av-DLBCL), and CD30 positivecutaneous lymphoproliferative disorder.
Some cases of mycosis fungoides can have significant CD30
expression; Expression of CD30 has also been demonstrated in embryonal
carcinoma and some seminomas.
7/22/2019 IHC- interpretare.ppt
20/185
CD30 in normal activated B cells CD 30 in HD
CD30 in carcinom embrionar
7/22/2019 IHC- interpretare.ppt
21/185
CD45 CD45 is a family of single chain transmembrane glycoproteins;
CD45 is expressed on cells of the human haematopoietic lineage with theexception of mature red cells.
CD45 is lost in megakaryocytes and plasma cells.
It is not detected on differentiated cells of other tissues.
CD45 has intrinsic tyrosine phosphatase activity and is essential fordevelopment and effector functions, playing an important role in signaltransduction, inhibition or upregulation of various immunological functions.
CD45 is detected in the large majority of haematolymphoid neoplasms, i.e.,leukaemias and malignant lymphomas.
Overall, about 90% of malignant lymphomas are CD45 positive. The
proportion is lower among precursor B-cell neoplasms (80% of B-ALL) andlarge cell anaplastic lymphomas, and only about 10% of plasmacyticneoplasms are positive.
In Hodgkin lymphoma, the L&H cells in the LP-type are always positive, whileReed-Sternberg cells in classic Hodgkin lymphoma are negative or only show afaint cytoplasmic staining.
7/22/2019 IHC- interpretare.ppt
22/185
CD68: antibodies detect a glycoprotein with a molecular
weight of approximately 110 kD, localized in thecytoplasm, often with relation to lysosomes.
Positive staining is seen in different types ofmacrophages of monocyte lineage and antibodies alsoreacts with myeloid precursor cells in the bonemarrow.
Expressed in fibrous-histiocytic tumours and
Langerhans cell histiocytosis, subtypes of myeloidleukaemia (depending on the Ab used), someepithelial neoplasms, epithelioid cells of somemalignant melanomas
7/22/2019 IHC- interpretare.ppt
23/185
CD68 in celule Kupffer
7/22/2019 IHC- interpretare.ppt
24/185
CD31
transmembrane glycoprotein, 130-140 kDa, alsodesignated platelet-endothelium cell adhesion molecule(PECAM-1), belonging to the immunoglobulin super family.
CD31 is strongly expressed in endothelial cells and weaklyexpressed in megakaryocytes, platelets, occasional plasmacells, lymphocytes (especially marginal zone B-cells,peripheral T-cells) and neutrophils.
CD31 is expressed in the vast majority of all types ofvascular neoplasms, such as hemangioendothelioma,angiofibroma, hemangioma, and angiosarcoma.
CD 31 is also expressed in most cases of Kaposi sarcoma
7/22/2019 IHC- interpretare.ppt
25/185
CD31 in hemangioendoteliom infiltrativ in
intestin
7/22/2019 IHC- interpretare.ppt
26/185
7/22/2019 IHC- interpretare.ppt
27/185
7/22/2019 IHC- interpretare.ppt
28/185
7/22/2019 IHC- interpretare.ppt
29/185
7/22/2019 IHC- interpretare.ppt
30/185
7/22/2019 IHC- interpretare.ppt
31/185
7/22/2019 IHC- interpretare.ppt
32/185
7/22/2019 IHC- interpretare.ppt
33/185
7/22/2019 IHC- interpretare.ppt
34/185
7/22/2019 IHC- interpretare.ppt
35/185
7/22/2019 IHC- interpretare.ppt
36/185
7/22/2019 IHC- interpretare.ppt
37/185
7/22/2019 IHC- interpretare.ppt
38/185
In carcinomas p63 is a very useful marker for squamous, urothelial andmyoepithelial differentiation. The same tumours are usually expressingcytokeratin 5. However, p63 often shows a more extended reaction.
An important criterion for the diagnosis of prostate adenocarcinoma is theabsence of basal cells. As these can be difficult to identify in routinesections, immunohistochemical identification of p63 and cytokeratin 5
may increase the sensitivity and specificity. Since negative staining for highmolecular weight cytokeratin(HMW-CK) in atypical prostate glands maynot be sufficient for a definitive diagnosis of malignancy, p63 may enhancethe ability to diagnose limited prostate cancer. However, p63 should beused in conjunction with HMW-CK and AMACR. A cocktail staining isapplicable. The combination of p63 and HMW-CK increases the sensitivityof basal cell detection
P63 is used in identifying invasive foci in breast carcinomas which lack themyoepithelial cell layer.
http://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/AMACR/AMACR.htmhttp://www.nordiqc.org/Epitopes/AMACR/AMACR.htmhttp://www.nordiqc.org/Epitopes/AMACR/AMACR.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Cytokeratins.htm7/22/2019 IHC- interpretare.ppt
39/185
P63 in prostata normala
7/22/2019 IHC- interpretare.ppt
40/185
CEA A glycoprotein comp of Ig superfamily (adhesion molecule);
In normal adult tissue, CEA is expressed in the apical border and, to alesser extent in the cytoplasm, of the columnar cells of colon, smallintestine, and stomach (surface epithelium, mucous neck cells andweakly in pyloric mucous cells), pancreatic ducts, secretory epitheliaof sweat glands, squamous epithelial cells of the tongue, esophagusand uterine cervix, and urothelium. The prostate is negative (apartfrom urothelium lined secretory ducts).
CEA is expressed in epithelial cell membranes and in the cytoplasm ofthe cells in almost all cases of colorectal adenocarcinoma as well as ahigh proportion of adenocarcinomas of the salivary glands, esophagus,
stomach, biliary tract, pancreas, small intestine, lung, uterine cervixand ovary (mucinous type).
7/22/2019 IHC- interpretare.ppt
41/185
7/22/2019 IHC- interpretare.ppt
42/185
Cadherins Cadherins are a family of calcium-dependent transmembrane
cell adhesion glycoproteins. In connecting cells they comprise apart of the zonula adherens and desmosomes.
The following tumours are almost always positive:
adenocarcinoma of colorectum, stomach, pancreas, prostate,endometrium, uterine cervix, and thyroid.
Among ovarian carcinomas, the mucinous type is almost alwayspositive, while varying positivity is seen in the other types.
Among breast carcinomas the ductal type (including thetubulolobular subtype) is almost always positive (at least in partof the tumour) while the lobular type is negative in 8590 %.
7/22/2019 IHC- interpretare.ppt
43/185
7/22/2019 IHC- interpretare.ppt
44/185
7/22/2019 IHC- interpretare.ppt
45/185
EMA in mezoteliom
7/22/2019 IHC- interpretare.ppt
46/185
Calretinin 32 kDa member of the superfamily of calcium-binding proteins.
It is abundantly expressed in central and peripheral neural tissues,particularly in the retina and in the neurons of the sensory pathways
it is also expressed in steroid producing cells (adrenal cortical cells,testicular Leydig cells, ovarian theca interna cells), testicular Sertolicells, rete testis, ovarian surface epithelium, some neuroendocrinecells, breast glands, eccrine sweat glands, hair follicular cells, thymicepithelial cells, endometrial stromal cells, and fat cells
Calretinin is also expressed by both normal and neoplastic mesothelialcells;
it is an useful marker for the identification of malignant mesotheliomas ofthe epithelial type and for the differentiation of these malignancies of lungadenocarcinoma
In calretinin positive cells, the protein is generally found in both thecytoplasm and nuclei.
7/22/2019 IHC- interpretare.ppt
47/185
Mezoteliom
7/22/2019 IHC- interpretare.ppt
48/185
7/22/2019 IHC- interpretare.ppt
49/185
7/22/2019 IHC- interpretare.ppt
50/185
7/22/2019 IHC- interpretare.ppt
51/185
7/22/2019 IHC- interpretare.ppt
52/185
7/22/2019 IHC- interpretare.ppt
53/185
Actina- clona HHF35 Labels myocardial, skeletal and smooth muscle cells as
well as myoepithelial cells. The antibody recognizesrhabdomyosarcomas, leiomyomas and
leiomyosarcomas, and also reacts with'myofibroblasts' in the stroma of certain tumorsincluding many carcinomas
Actina - clona 1A4
This antibody labels smooth muscle cells,
myofibroblasts and myoepithelial cells, and is usefulfor the identification of leiomyomas, leiomyosarcomasand pleomorphic adenomas
7/22/2019 IHC- interpretare.ppt
54/185
Actina- LMS
7/22/2019 IHC- interpretare.ppt
55/185
7/22/2019 IHC- interpretare.ppt
56/185
Caldesmon in leiomiom
7/22/2019 IHC- interpretare.ppt
57/185
Desmin Desmin is an intermediate filamentprotein (53
kDa) expressed in all striated muscle cells andmost smooth muscle cells; Desmin play no role incontractility but serves to maintain the orientationof actin and myosin filaments and may also play arole in nuclear transcription
Desmin is detected in most tumours of myogenicorigin, e.g., leiomyosarcoma andrhabdomyosarcoma
http://www.nordiqc.org/Epitopes/Cytokeratins/Intermediate_filaments.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Intermediate_filaments.htm7/22/2019 IHC- interpretare.ppt
58/185
7/22/2019 IHC- interpretare.ppt
59/185
7/22/2019 IHC- interpretare.ppt
60/185
Vimentina Vimentin (57 kDa) is the most ubiquituos intermediate filamentprotein and the first to be expressed during cell
differentiation. All primitive cell types express vimentin but in most non-mesenchymal cells it is replaced by otherintermediate filament proteins during differentiation.
Vimentin is expressed in a wide variety of mesenchymal cell types fibroblasts, endothelial cells etc., and in anumber of other cell types derived from mesoderm, e.g., mesothelium and ovarian granulosa cells.
However, in non-vascular smooth muscle cells, vimentin is often replaced by desmin. In striated muscle, vimetin isalso replaced by desmin. However, during regeneration, vimentin is reexpressed.
Cells of the lymfo-haemopoietic system (lymphocytes, macrophages etc.) also express vimentin, sometimes in
scarce amounts. Vimentin is also found in mesoderm derived epithelia, e.g. kidney (Bowman capsule), endometrium and ovary
(surface epithelium), in myoepithelial cells (breast, salivary and sweat glands), an in thyroid gland epithelium
Vimentin is present in many different neoplasms but is particulary expressed in those originated frommesenchymal cells. Sarcomas e.g., fibrosarcoma, malignt fibrous histiocytoma, angiosarcoma, and leio- andrhabdomyosarcoma, as well as lymphomas, malignant melanoma and schwannoma, are virtually always vimentinpositive .
Mesoderm derived carcinomas like renal cell carcinoma, adrenal cortical carcinoma and adenocarcinomas from
endometrium and ovary usually express vimentin. Also thyroid carcinomas are vimentin positive.
Any low differentiated or sarcomatoid carcinoma may express some vimentin.
http://www.nordiqc.org/Epitopes/Cytokeratins/Intermediate_filaments.htmhttp://www.nordiqc.org/Epitopes/Cytokeratins/Intermediate_filaments.htm7/22/2019 IHC- interpretare.ppt
61/185
7/22/2019 IHC- interpretare.ppt
62/185
7/22/2019 IHC- interpretare.ppt
63/185
7/22/2019 IHC- interpretare.ppt
64/185
Myo D1 The MyoD1 protein is a 45 kDa nuclear phosphoprotein
which induces myogenesis through transcriptionalactivation of muscle-specific genes;
Nuclear expression of MyoD1 is restricted to skeletalmuscle tissue and has been demonstrated to be a sensitivemarker of myogenic differentiation;
The antibody strongly labels the nuclei of myoblasts indeveloping skeletal muscle tissue, whereas the majority ofadult skeletal muscle is negative;
MyoD1 immunostaining has been demonstrated in themajority of rhabdomyosarcomas of various histologicalsubtypes.
7/22/2019 IHC- interpretare.ppt
65/185
Myogenin
Myogenin belongs to a family of regulatory proteins
essential for muscle development.
Expression of myogenin is restricted to cells of skeletalmuscle origin, and appears to be inversely related to
the degree of cellular differentiation.
The antibody recognizes an epitope located in the
amino acid region 138-158 of the myogenin protein. It labels nuclei in the majority of human
rhabdomyosarcomas and Wilms' tumors
7/22/2019 IHC- interpretare.ppt
66/185
7/22/2019 IHC- interpretare.ppt
67/185
7/22/2019 IHC- interpretare.ppt
68/185
7/22/2019 IHC- interpretare.ppt
69/185
AFP (alfa feto protein) - a 70 kDa glycoprotein, synthesized by the cells of the
embryonic yolk sac, fetal liver and fetal intestinaltract.
Expression of AFP has been demonstrated in manyhepatocellular carcinomas and in gonadal andextragonadal germ cells tumors, including yolk sactumors.
The antibody may be useful for the identification ofnon-neoplastic and neoplastic liver diseases, yolk sactumors and mixed germ cell tumors
7/22/2019 IHC- interpretare.ppt
70/185
AFP in tumora sac yolk
7/22/2019 IHC- interpretare.ppt
71/185
7/22/2019 IHC- interpretare.ppt
72/185
7/22/2019 IHC- interpretare.ppt
73/185
7/22/2019 IHC- interpretare.ppt
74/185
7/22/2019 IHC- interpretare.ppt
75/185
7/22/2019 IHC- interpretare.ppt
76/185
7/22/2019 IHC- interpretare.ppt
77/185
7/22/2019 IHC- interpretare.ppt
78/185
7/22/2019 IHC- interpretare.ppt
79/185
WT-1 The WT1 gene located at chromosome 11p13 codes for a transcription factor, a DNA-binding
nucleoprotein, 52-62 kDa, that plays a role primarily in the development of genitourinaryorgans.
In normal epithelia, nuclear WT1 expression is largely restricted to ovary (surface epitheliumand inclusion cysts) and fallopian tube, while WT1 is not found in endometrial or cervicalepithelium. As regards nonepithelial cells, nuclear WT1 is found in mesothelium and somesubmesothelial stromal cell
Among epithelial tumours, nuclear WT1 is strongly expressed in ovarian serous carcinoma(97% of the tumours, usually a widespread reaction), peritoneal serous carcinoma, ovariantransitional carcinoma, and about half of ovarian endometrioid carcinoma (grade 2 and 3 butnot grade 1). Also metanephric adenoma is positive
Among nonepithelial tumours, nuclear WT1 is strongly expressed in the large majority ofmalignant mesothelioma and sex cord-stromal tumours.
Nuclear WT1 has moreover been demonstrated in Wilms' tumour (about 50% of the cases,involving epithelial, stromal and blastemal elements), malignant rhabdoid tumour,
adenomatoid tumour, endometrial stromal sarcoma, uterine leiomyosarcoma, mixedmullerian tumour, as well as in some malignant lymphomas (lymphoblastic and Burkitt'slymphoma), and most cases of acute leukaemia.
7/22/2019 IHC- interpretare.ppt
80/185
WT-1 in mezoteliul normal WT-1 in mezoteliom
7/22/2019 IHC- interpretare.ppt
81/185
7/22/2019 IHC- interpretare.ppt
82/185
Melan A in epiteliul normal Melan A in melanom
7/22/2019 IHC- interpretare.ppt
83/185
7/22/2019 IHC- interpretare.ppt
84/185
7/22/2019 IHC- interpretare.ppt
85/185
7/22/2019 IHC- interpretare.ppt
86/185
Inhibin is a dimeric glycoprotein hormonecomprised of an and a subunit.
It is produced by ovarian granulosa cells andinhibits the production or secretion of pituitary
gonadotropins, particularly follicle-stimulatinghormone.
The antibody was raised against the terminal 1-32amino acid sequence of the inhibin subunit.
In abnormal ovarian tissues, inhibin is asensitive marker for the majority of sex-cord-stromal tumors.
7/22/2019 IHC- interpretare.ppt
87/185
TTF-1 in carcinom tiroidian folicular
7/22/2019 IHC- interpretare.ppt
88/185
7/22/2019 IHC- interpretare.ppt
89/185
7/22/2019 IHC- interpretare.ppt
90/185
The Ki-67 antigen is a large nuclear protein (345,395 kDa) preferentially expressed during all active
phases of the cell cycle (G1, S, G2and M-phases),
but absent in resting cells (G0-phase). In diagnostic histopathology and cell biology,
antibodies against the Ki-67 antigen have proven
valuable by allowing direct monitoring of the
growth fraction of normal and neoplastic cells
7/22/2019 IHC- interpretare.ppt
91/185
Ki-67 in mucoasa colonica normala
7/22/2019 IHC- interpretare.ppt
92/185
7/22/2019 IHC- interpretare.ppt
93/185
HMB-45 Vimentina
7/22/2019 IHC- interpretare.ppt
94/185
7/22/2019 IHC- interpretare.ppt
95/185
Carcinom cu celule Merkel: Aspect monomorf ; celule cu citoplasma putina ;
nuclei rotunzi, vacuolati, nucleolati, cromatina in saresi piper; numerosi nuclei fragmentati, stroma cunumeroase vase cu endoteliu inalt
IHC : poz pentru: citokeratine cu greutate mica (CK 20- aspect punctiform,
perinuclear, rar intalnit in alte organe)
Neurofilamente;
Enolaza neuron specifica Cromogranina, sinaptofizina, VIP
Diagn. Diferential cu carc neuroendocrin cu cel mici de plaman(CK7 poz si TTF poz);
7/22/2019 IHC- interpretare.ppt
96/185
7/22/2019 IHC- interpretare.ppt
97/185
7/22/2019 IHC- interpretare.ppt
98/185
7/22/2019 IHC- interpretare.ppt
99/185
7/22/2019 IHC- interpretare.ppt
100/185
7/22/2019 IHC- interpretare.ppt
101/185
Plaman si pleura
7/22/2019 IHC- interpretare.ppt
102/185
Plaman si pleura
Mezoteliom AA pozitiv/ PAS negativ
IHCpoz pt. : calretinin, CK 5/6 si WT1, EMA
neg: CEA, B72.3 si MOC-31 (poz in adenoc)
7/22/2019 IHC- interpretare.ppt
103/185
7/22/2019 IHC- interpretare.ppt
104/185
TTF in adenoc pulmonar
7/22/2019 IHC- interpretare.ppt
105/185
TTF in adenoc pulmonar
7/22/2019 IHC- interpretare.ppt
106/185
Carcinom cu dezvoltare lepidica (fostul carcinom bronhiolo-alveolar) !! Subtipul mucinos este CK 20 poz si TTF-1poz
MUC3 si MUC6 poz ( diagn. diferential cu ADK);
Carcinomul cu cel mica:
- caracteristic: nuclei mulati, hipercromatici, cromatina fina,nucleoli absenti, citoplasma putina, mitoze numeroase ( posibil caaceasta celula apare din celule epiteliale si in cursul tranformarii malignesufera diferentiere endocrina).
IHC: - pozitivitate variabila pentru : neurofilamente, Leu-7, cromogranina,sinaptofizina, enolaza neuron specifica (marker seric de asemenea!),keratine.
CD99 - neg (dgn dif cu PNET/ sarcom Ewing)
TTFpoz in aprox. 85% de cazuri;
7/22/2019 IHC- interpretare.ppt
107/185
7/22/2019 IHC- interpretare.ppt
108/185
7/22/2019 IHC- interpretare.ppt
109/185
Sinaptofizina
7/22/2019 IHC- interpretare.ppt
110/185
Sinaptofizina
7/22/2019 IHC- interpretare.ppt
111/185
Tumora cu celule clare (sugar cell tumor) HMB-45, enolaza, sinaptofizina, focal S-100.
Metastaze!
Tiroida
7/22/2019 IHC- interpretare.ppt
112/185
Tiroida
Carcinom papilar tiroidian CK 7+/CK 20
CK19 +
HMW CK 34betaE12 +
Tireoglobulina, TTF-1 + (intensitate mai scazuta de
obicei decat in carc folicular);
Alti markeri poz: S100, EMA, CEA, galectin, ER,HBME-1;
7/22/2019 IHC- interpretare.ppt
113/185
TTF in carc folicular tiroidian
7/22/2019 IHC- interpretare.ppt
114/185
metastatic
7/22/2019 IHC- interpretare.ppt
115/185
7/22/2019 IHC- interpretare.ppt
116/185
Tract digestiv
7/22/2019 IHC- interpretare.ppt
117/185
Gastric carcinoma MUC-1+: tip intestinal;
MUC5AC+: tip difuz; (cardia)
MUC2+ : tip mucinos CEA, EMA, LMW CK + ( dar cateodata CK13, 16);
CK7 + (70% din cazuri);
CK20 + (20%);
Hepatoid ADK: Hep- Par-1+ si AFP +
7/22/2019 IHC- interpretare.ppt
118/185
CK7
CEA
7/22/2019 IHC- interpretare.ppt
119/185
Tumori stromale gastrice: Origine: celule Cajal, celule de origine
mezodermica, cu rol in coordonarea activitatatii
contractile a muschiului neted; IHC :
CD117 +
CD34 +
Ki-67
CD117
7/22/2019 IHC- interpretare.ppt
120/185
CD117
7/22/2019 IHC- interpretare.ppt
121/185
Tumori cu celule endocrine WDNET (tumora endocrina bine diferentiata su
carcinoid) :
arhitectura microglandulara, trabeculara, mai rarinsulara
Nuclei regulati si normocromatici, rare mitoze, necroza
absenta, vascularizatie bogata.
IHC : - NSE, CRG, SYN, keratine
7/22/2019 IHC- interpretare.ppt
122/185
Carcinom neuroendocrin bine diferentiat Aceleasi caracteristici microscopice + trasaturi
de atipie: necroza, mitoze (>2%), caracter invaziv
Aceiasi markeri neuroendocriniCarcinom cu celule mici ( carcinom endocrin slab
diferentiat)analog carc cu celule mici pulmonar
- comportament agresiv (Ki-67 >30%),
- de obici cromogranina este absenta sau
prezenta focal, NSE si sinaptofizina intens poz
Intestin subtire
7/22/2019 IHC- interpretare.ppt
123/185
Tumori endocrine: Origine in celulele endocrine ale glandelor
Lieberkuhn;
Pozitivitate: CEA, CK7(10%), CK20 (20%); Markeri neuroendocrini: Syn, NSE, CRG, PGP9.5,
Leu7;
7/22/2019 IHC- interpretare.ppt
124/185
Boala celiaca (sprue) Atrofia vilozitatilor, infiltrat inflamator cu limfocite Tc
(CD3 si CD8 pozitive) in corion si intraepitelial;
!sprue refractar se caracterizeaza prin prezenta LTgamma delta
Boala Whipple
- Generata de Tropheryma whipelii;
- Mi: plaje de macrofage in lamina propria ce determinadistorsiuni arhitecturale ale vilozitatilor intestinale si
care contin in citoplasma material PAS pozitiv datoritabacililor;
- IHC : CD4/ CD8 LT scazut;
7/22/2019 IHC- interpretare.ppt
125/185
GIST
ADK
Limfoame
7/22/2019 IHC- interpretare.ppt
126/185
Intestin gros Adenocarcinom clasic :
MUC1 si MUC3 poz
CK20 poz/ CK 7 neg CEA poz
CDX2 poz (poz de asemenea in carcinomul mucinos
ovarian si de vezica urinara);
Tag-72 (mAb 72.3) poz (de asemenea si in polipiihiperplazici si adenomatosi si chiar si in mucoasa
normala).
7/22/2019 IHC- interpretare.ppt
127/185
CDX2
nuclear
marker
7/22/2019 IHC- interpretare.ppt
128/185
7/22/2019 IHC- interpretare.ppt
129/185
7/22/2019 IHC- interpretare.ppt
130/185
Canal anal Carcinom scuamos
IHC- HPV
Boala Paget: CK7 poz, CK20+/-, GCDFP+/- ( pattern diferitde adenocarcinomul clasic care este CK7-).
Melanom
7/22/2019 IHC- interpretare.ppt
131/185
Ficat: Carcinom hepatocelular:
Pozitivitate pentru : AFP, keratine: CK8 (CAM 5.2) si CK7 (intr-un nrmic de cazuri), EMA, Hep-Par-1 (mAb ce interactioneaza cu oproteina citoplasmatica inca necunoscuta prezenta in hepatocitenormale si neoplazice).
MOC31negativ (pozitiv in colangiocarcinom si metastazehepatice);
CEAnegativ sau focal pozitiv (ajuta in diagnosticul diferentialpentru ca este pozitiv in carcinomul de cai biliare si in carcinoamemetastatice) ! Pozitivitate de tip canalicular!
Pozitivitate de asemenea la ER si AR.
Tumorile bine diferentiate: laminina, fibonectina
Vasele sunt pozitive la CD34, ceea ce nu se intampla pentrusinusoidele hepatice.
7/22/2019 IHC- interpretare.ppt
132/185
7/22/2019 IHC- interpretare.ppt
133/185
Colangiocarcinom Coloratie pentru mucina pozitiva (!)
IHC- pozitivitate pentru CEA (pozitivitate
citoplasmatica si luminala !), EMA, Cam 5.2 (LMWCK), AE1/AE3 (HMW CK).
Profilul CK in colangiocarcinomul intrahepatic
(CK7+/CK20+) este diferit fata de
colangiocarcinomul extrahepatic (CK7+/CK20-)
7/22/2019 IHC- interpretare.ppt
134/185
7/22/2019 IHC- interpretare.ppt
135/185
FVIII related antigen
7/22/2019 IHC- interpretare.ppt
136/185
Pancreas Adenocarcinom ductal- pozitivitate pentru:
EMA, keratine (CK 7,8, 18, 19, 15, 17, 20, 5/6, 10, 13)
CEA, CA19-9, B72.3 MUC1 (dgn. diferential cu carcinomul papilar
intraductal, carcinomul ampular si cel mucinos)
Glanda suprarenala
7/22/2019 IHC- interpretare.ppt
137/185
Tumori de corticosuprarenala (adenom/carcinomde corticosuprarenala):
Pozitivitate pentru : vimentina, syn, inhibina si MelanA
Negativitate pentru: cromogranina Pozitivitate de asemenea pentru calretinin (focal), bcl-
2, keratine ( in special adenoamele, focal si sporadic)
!!Adenoamele au expresie mai scazuta pentru
vimentina si mai crescuta pentru LMW CK. Negative pentru :EMA, CEA, B72.3
7/22/2019 IHC- interpretare.ppt
138/185
7/22/2019 IHC- interpretare.ppt
139/185
Tract genital femininC i
7/22/2019 IHC- interpretare.ppt
140/185
Cervix
CIN P16- inhibitor de CDK inactivat de HPV-E7, ceea ce
implica ca supraexpresia P16 indica prezenta HPV de
risc inalt- in leziunile CIN II si CIN III mai mult de
jumatate din grosimea epiteliului prezinta pozitivitate(2/3 -1/1);
exista leziuni de grad inalt p16 negative !!!
KI-67in mod normal prezent numai la nivelul
stratului parabazal; in CIN IIindica rata deproliferare inalta; in CIN IIIprezent in toata
grosimea epiteliului.
7/22/2019 IHC- interpretare.ppt
141/185
Carcinom scuamos invaziv Pozitivitate pentru :
Keratine
P63
CEA
Adenocarcinom endocervical:
-! Coloratii histochimice si marcaje IHC pentru mucina poz (prezdifuz intracelular)
- pozitivitate pentru CEA
- negativitate pentru vimentina
- negativitate sau prez slaba pentru ER, PR
-HPV prezent (col IHC pentru HPV sau p16)Toate acestea ajuta la diagnosticul diferential cu adenoc. endometrioidde endometru! (atentie la carcinomul seros de endometru care estepozitiv la p16)
7/22/2019 IHC- interpretare.ppt
142/185
(Adeno)carcinom mezonefric:
CD10+
Calretinin +
Carcinom neuroendocrin- NSE +
- Cromog + (cazurile bine diferentiate)
- Syn +
- Serotonin
- CEA
- keratine
7/22/2019 IHC- interpretare.ppt
143/185
Uter Adenocarcinom endometrioid:
Keratine 7, 8, 18, 19 +
Vimentina + (65-80%)
CEA + in ariile de metaplazie scuamoasa (! Diagn diferential cu
adenoc endocervical)
CA125 +
ER, PR (pozitivitatea cea mai mare in adenoc endometrioid , urmatde carcinomul papilar seros si carcinomul cu celule clare);
! Carc adenoscuamos de grad inalt este neg la ER, PR;
!WT-1 pozitiv in carc papilar seros ovarian si neg in carc papilarseros de endometru si alte carcinoame primare de endometru
7/22/2019 IHC- interpretare.ppt
144/185
Tumori stromale uterine Mi
Constit din celule mici uniforme, asem celor din stroma endom, invelite defibre de reticulina;
Arhitectura multinodulara
Arteriole spiralate, unele cu pereti hialinizati;
Focare de hialinizare si izolate celule spumoase;
Absenta vaselor mari cu perete gros
Przenta spatiilor de clivare
- IHC:
- CD10 +
- vimentina +
- actin + (de obicei)
- ER, PR +- Desmin, -/ + (uneori prez. focal);
- h-Caldesmon
- S100 -
7/22/2019 IHC- interpretare.ppt
145/185
Tumori combinate musculare si stromale(stromomioma):
MIaspect caract de starbust a componentei
musculare netede IHC : CD10+
Desmin, h-Caldesmon poztive pe ariile starbust
7/22/2019 IHC- interpretare.ppt
146/185
Tumori uterine similare tumorilor ovariene cuorigine in cordoanele sexuale:
IHC:
CD99 + Inhibin +
7/22/2019 IHC- interpretare.ppt
147/185
Tumori mixte mulleriene maligne: Aspect mixt constituit din elemente
carcinomatoase (de tip glandular : endometrioid,
celula clara sau papilar seros) si elemente
sarcoma-like homologe (de tip fibro sau
leiomiosarcom) sau heterologe ( condro sau
osteosarcom);
Pot fi intalnite elemente scuamoase, slabdiferentiate;
7/22/2019 IHC- interpretare.ppt
148/185
7/22/2019 IHC- interpretare.ppt
149/185
Tumori de muschi neted(leiomiom/leiomiosarcom)
Actina, desmin, calponin, h-caldesmon +
Vimentin+ LMW keratins (CAM 5.2)+ (de obicei)
ER, PR + ( cu intensitate mai mare in leiomioame
decat in leiomiosarcoame);
7/22/2019 IHC- interpretare.ppt
150/185
Ovar Tumori epiteliale seroase
IHC
CK7+
CK20-
CK , 18, 19, EMA, B72.3 +
S100 + in special in t. borderline
WT-1+ difuz in carcinoamele seroase (la fel in mezotelioameperitoneale, mai putin carcinoamele endometrioide si de
obicei negativ in carcinoamele mucinoase); Ca125 +
CEA -
7/22/2019 IHC- interpretare.ppt
151/185
7/22/2019 IHC- interpretare.ppt
152/185
Carcinom endometrioid IHC:
Keratin +
EMA +
Vimentin +
CEAsau slab +
7/22/2019 IHC- interpretare.ppt
153/185
Tumori cu celule germinale: Tumora de sac yolk
IHC:
AFP+
Pankeratin +
CK 7
WT-
CEApattern canalicular cu Ac policlonal
7/22/2019 IHC- interpretare.ppt
154/185
Carcinom embrionar : IHC :
hCG +
CK 7 + (pentru un subset de celule trofoblastice)
Teratom matur/imatur
IHC:
- GFAP + in structurile nervoase mature si imature (!poate
fi pozitiv si in condrocite)
7/22/2019 IHC- interpretare.ppt
155/185
7/22/2019 IHC- interpretare.ppt
156/185
IHC utila uneori in diagnosticul diferential tumora primara/ tumora secundara ovariana
ex. Met. de ADK de colon
CK7-/ CK20+
CEA +
CA125
MUC 2 +
T. primara mucinoasa ovariana
- CK 7+- CK20 + focal, uneori
- CEA
- CA 125 +
- MUC 5AC+
!Atentie la carc. gastrice , pancreatice, etc
GGL limfatic
7/22/2019 IHC- interpretare.ppt
157/185
NLPHL Celula popcorn
Pozitivitate pentru CD19, CD20, CD22, CD45RA,
CD45; Uneori pozitivitate pentru CD30 si EMA
CD15 negativ
7/22/2019 IHC- interpretare.ppt
158/185
7/22/2019 IHC- interpretare.ppt
159/185
NHL
7/22/2019 IHC- interpretare.ppt
160/185
SLL Arhitectura stearsa de o proliferare de limfocite
mici cu citoplasma putina, cromatina grunjoasa,nucleoli absenti si activitate mitotica redusa
IHC: CD20, CD22, CD19, CD79a +
CD5+
CD23+
CD43+
Ciclina D
7/22/2019 IHC- interpretare.ppt
161/185
Limfom limfoplasmocitic Proliferare de limfocite mici, plasmocite si limfocite
plasmacitoide cu localizare im maduva osoasa simaduva hematopoietica
Prezenta de corpi Dutcher (pseudoincluzii nuclearePAS+)
IHC
IgM in citoplasma +
CD5-, CD10-, CD23- CD19, CD20, CD22, CD79a+
CD138+
7/22/2019 IHC- interpretare.ppt
162/185
Mielom plasmocitar Maduva osoasa30% din volum ocupat de
plasmocite; corpi Russell;
IHC: CD79a, VS38c, CD138+
K, monoclonale
CD19
CD20, CD117, CD10 -/+
7/22/2019 IHC- interpretare.ppt
163/185
Plasmocitom extraosos Localizare extramedulara; diagnosticul se pune
prin excluderea unui limfom MALT cu diferentiere
plasmacitoida
7/22/2019 IHC- interpretare.ppt
164/185
Limfom folicular proliferare constituita din centroblaste/centrocite cu arhitectura foliculara, cel
putin partial
Foliculii neoplazici sunt slab definiti, cu zona de manta discreta sau absenta
Cele 2 tipuri de celule (centroblaste si centrocite) sunt difuz distribuite si nupolarizate, ca in centrii germinali reactivi;
Macrofagele cu corpi tingibili sunt de obicei absente
IHC:- CD19, CD20, CD22, CD79a +, IgM+/-
- bcl2, bcl6, CD10+
- CD5-
- CD21 si CD23detecteaza FDC
- gradul 3B poate fi lipsit de CD10, dar retine expresia bcl6
- bcl2- exprimat in 85-90% din LF gradul 1 si 2, dar in numai 50% dinlimfoamele grad 3
7/22/2019 IHC- interpretare.ppt
165/185
Limfom de manta Proliferare limfoida monomorfa cu arhitectura difuza,
vag nodulara a zonei de manta sau, rar, foliculara;
Este alcatuita din celule mici sau medii, cu usoareneregularitati ale conturului nuclear (asemanatoare
centrocitelor) IHC
CD5, CD7, bcl-2, ciclina D1 +
sIgM/IgD+
Restrictie k/
CD10, bcl-6
Fenotipuri aberante: CD5-
7/22/2019 IHC- interpretare.ppt
166/185
Limfom cu celule mari B difuz: Neoplasm cu celule B cu nucleu egal sau mai mare decat nucleul
macrofagelor sau mai mare de 2 ori decat al unui limfocit normal;
Etiologie: de novo sau prin progresia CLL/SLL, FL, MZL, NLPHL
Variante : centroblastica, imunoblastica, anaplazica (celule mari, cunuclei pleomorfi, bizari, asem cel S-R);
IHC:- CD19, CD20, CD22, CD79a +/-
- IgM>IgG>IgA
- CD30 + (varianta anaplazica)
- CD5 + (10% din cazuri)
- CD10 (30-60% din cazuri)
- bcl-6 + (60-90% din cazuri)
- ki-67>40%!!
7/22/2019 IHC- interpretare.ppt
167/185
Limfom Burkitt Proliferare cu rata de dedublare f crescuta (mitoze
multe!), compusa din celule monomorfe cu
translocatie myc
IHC
CD19, CD20, CD22, CD10, bcl-6, CD38 +
Translocatie myc la regiunea IGH
7/22/2019 IHC- interpretare.ppt
168/185
Limfom MALT = limfom de zona marginala extraganglionar
Mi: - limfom extraganglionar alcatuit din limfocite mici centrocitlike,celule centroblast like precum si imunoblaste, cu extensie in zoneleinterfoliculare In tes epiteliale, celulele infiltreaza epiteliul, generand leziuni limfoepiteliale;
IHC:
- IgM, CD20, CD79a +
- CD5, CD10, CD23, ciclina D1-
- ! Rareori CD5+
- CD21 si CD35 +, evidentiind retele de celule dendritice foliculare aflate infoliculii colonizati;
- restrictie de lanturi usoare /(prin care se face diagnosticul diferential cuinfiltrate limfoide benigne)
- abs CD5utila in diagn diferential cu MCL si CLL- abs ciclinei D1- utila in diagn diferential cu MCL
- abs CD10utila in diagn diferential cu FCL
7/22/2019 IHC- interpretare.ppt
169/185
Limfom cu celule T periferice NOS IHC:
CD5, CD7, CD4, CD8+
CD30, CD15 + exceptional
Rearanjare TCR prezenta
Limfom anaplazic cu celule mari ALK pozitiv
IHC:
- CD30 + (marcaj membranar si golgian)- ALK+ (de preferat mAb)
7/22/2019 IHC- interpretare.ppt
170/185
Limfom limfoblastic neoplazie constituita din celule precursoare
(limfoblaste) cu citoplasma redusa si cromatina
laxa sau condensata
IHC
CD19, cCD79a, cCD22, CD10+
Pax+
Tdt +
Tumori tesuturi moi
7/22/2019 IHC- interpretare.ppt
171/185
T fibroase (fibromatoza, fibrosarcom) Contin fibroblaste, miofibroblaste si matrice
extracelulara (colagen si subst fundam)
IHC- vimentina, actina, desmin (in masura mai
mica), colagen
7/22/2019 IHC- interpretare.ppt
172/185
T fibrohistiocitare Derivate probabil din fibroblaste;
Datorita lipsei markerilor specifici pentru acest lineaj,
diagnosticul se bazeaza pe lipsa markerilor pentru alte
lineaje ( DFSPCD34+++; neurofibromasS100);
Poate fi identificata imunoreactivitate pentru :
Vimentina, CD68, feritina, antitripsina
Focal: Keratine, desmina, NF (HFM angiomatoid exp desmina
in 50% din cazuri!)
Dgn de HFM este mentinut doar in 50% din cazuri
7/22/2019 IHC- interpretare.ppt
173/185
7/22/2019 IHC- interpretare.ppt
174/185
T. de muschi neted SMA+ (mai sensibila)
Desmina+
Vimentina + Caldesmona:
pozitiva in leiomiom, leiomiosarcom, t. glomica
Negativa in t. rabdoide, t.desmoide
! Alti markeri (CK cu GM mica, S100, Leu-7 si chiar CD34 )pot fi
prezenti inconstantatentie la interpretare
7/22/2019 IHC- interpretare.ppt
175/185
T. muschi striat:
Desmin
Actin sarcomeric
Miogenin (MyoD1)
Miozin
Mioglobin
Vimentin
Focal exprim: CK, protein S100 (in t. slab diferentiate) iprotein asociat neurofilamentelor
Ki-67factor important
7/22/2019 IHC- interpretare.ppt
176/185
Sarcom Ewing extrascheletalPozitiv: Vim, CD99
Negativ: Des, Act, LCA, GFAP, Mio, ChrA
Tumor primitiv neuroectodermic
Pozitiv: CD99, NF, Syn
Negativ: markeri musculari
Condrosarcom mezenchimal
Pozitiv: CD99, S100, NSENegativ: CK, Des, Act, EMA, Syn
7/22/2019 IHC- interpretare.ppt
177/185
Tumori ale tecii nervului: Neurofibromul:
Proliferare combinat de elemente ale nervului periferic
IHC
NSE + axoni
S100 + Schwann
Vim + fibroblaste
EMA + celule perineuriale
CD34 + celule ?
7/22/2019 IHC- interpretare.ppt
178/185
Schwannomul
ncapsulat
IHC: S100, colagen IV, laminin, vim, rar CD68 i GFAP
Tip A
Celule fusiforme
Palisad
Corpi Verocay
Tip B
Arii edematoase
Spaii chistice
S100
Schwannom celular
7/22/2019 IHC- interpretare.ppt
179/185
Tumora maligna a tecii nervului periferic: Pozitiv: S100 (50-70%), CD57 (50%), proteina
bazic a mielinei
EMA negativ, pan.CK +/-, CK7/19-
Diferenial: leiomiosarcom (S100), sarcom sinovial
(S100, CK7/19), melanom cu celule duziforme
7/22/2019 IHC- interpretare.ppt
180/185
T. vasculare Hemangioendoteliomul :
Keratine, vim, CD31, +
CD34+/-
Angiosarcomul:CD31+
Limfangiom:
CD31, CD34, FVIIIrAg
Limfangiomiomul:Act, Des, HMB45
7/22/2019 IHC- interpretare.ppt
181/185
Prostata AMACR (p504S)
Marker pozitiv al celulelor neoplazice si preneoplazice (PIN)util in diagn
P63, CK 34E12 (CK903), CK 5/6
- Markeri ai celulelor bazale, elimina diagn de leziune malignain leziuni precum atrofia si adenoza
! In prezent se face dublu marcaj p63-AMACR (p504S).
PSA are rol in diagnosticul tumorilor slab diferentiate
dezvoltate in regiunea cervico-prostatica precum si indiagnosticul tumorilor metastatice (! Poate fi neg dupahormonoterapie).
T genitale masculine
7/22/2019 IHC- interpretare.ppt
182/185
Tumori cu celule germinale
Seminomul:
IHC:
PLAP+ (pozitivitate membranara in 90% din cazuri) C-kit (CD117)+
CD30, AFP, CK-
7/22/2019 IHC- interpretare.ppt
183/185
Carcinomul embrionar: IHC:
CD30+
CK AE1/AE3, CK4,17,18,19+
PLAP + focal (membranar si/sau citoplasmatic)
AFP-
CD117-
7/22/2019 IHC- interpretare.ppt
184/185
T de sac yolk IHC:
AFP+
CK+ (pozitivitate constanta, puternica)
CD117 + in aprox 80% din cazuri
CD30 -
7/22/2019 IHC- interpretare.ppt
185/185
T de cordoane sexuale: IHC:
Inhibina, CD99, calretinina +
vimentina +
CK - sau cu pozitivitate variabila